Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEAT-AML
2023-509019-97-00Phase 2Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of hydroxyurea in acute myeloid leukemia (AML), sponsored by Karolinska University Hospital. Planned start Mar 2024; status: authorised.
02
Drugs
hydroxyurea
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-509019-97-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509019-97-00.